MCUR.C

Today Maddy speaks with the president & CEO of Mindcure (MCUR.C), Kelsey Ramsden. Kelsey breaks down the burgeoning therapeutic world of psychedelics and outlines Mindcure’s uniquely comprehensive approach of…
Mind Cure Health (MCUR.C) announced the development of two proprietary ketamine-enhanced protocols specifically for pain management and another for depression, according to a press release.   Depression is basically…
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to…
Mind Cure (MCUR.C), a leader in advanced proprietary technology for psychedelic therapy, has provided updates regarding its financial position, near-term revenue strategy, and a timeline for iSTRYM’s market launch….
Mind Cure Health (MCUR.C) has entered into a partnership and licensing deal with SOMA Breath Inc. “We think it is important to give individuals options in building their mental…
Mind Cure (MCUR.C) has partnered with Lucid Inc. to design custom psychedelic music experiences for the Company’s iSTRYM technology. “We are building first-of-its-kind functionality by pairing AI-driven music scapes…
Mind Cure Health (MCUR.C) has entered into a partnership with Speak Ai to bolster the Company’s iSTRYM platform. “We are proud to partner with MINDCURE today to help build…
Mind Cure (MCUR.C) has filed a provisional patent application with the U.S. Patent and Trademark Office for the Company’s iSTRYM proprietary digital therapeutics (DTx) tool. “When people think of…
Mind Cure Health (MCUR.C) started their first stage of manufacturing pharma-grade ibogaine for both preclinical and clinical research today, according to a press release. Ibogaine is a psychoactive compound…
Mind Cure Health (MCUR.C) launched iSTRYM, a digital therapeutic tool for providing data regarding patient care, procedures and protocols, as well as other resources for mental health care workers…